Is Karen Wyckoff Rein In Sarcoma Legit?

Karen Wyckoff Rein In Sarcoma demonstrates a generally healthy financial position with consistent revenue generation and asset growth over the past decade. The organization's latest reported revenue of $606,354 in 2023, with expenses of $554,483, indicates a surplus, contributing to its robust asset base of $1,175,955. While there was a slight dip in assets from $1,199,056 in 2022, the overall trend shows responsible financial management and accumulation of resources to support its mission. The organization's consistent reporting of 0% officer compensation across all filings suggests a strong commitment to directing funds towards programs rather than executive salaries, enhancing its spending efficiency and transparency. The organization's financial health appears stable, with assets consistently exceeding liabilities, indicating good solvency. The absence of officer compensation is a significant positive indicator of efficiency and a focus on mission-driven spending. The consistent filing of IRS Form 990s over 13 periods also points to a high level of transparency and adherence to regulatory requirements, allowing for public scrutiny of its financial operations. This consistent reporting and lack of executive compensation contribute to a positive assessment of its financial stewardship.